Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H2 2019’, provides an overview of the Interstitial Cystitis (Painful Bladder Syndrome) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Interstitial Cystitis (Painful Bladder Syndrome) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Interstitial Cystitis (Painful Bladder Syndrome)

– The report reviews pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome) by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Interstitial Cystitis (Painful Bladder Syndrome) therapeutics and enlists all their major and minor projects

– The report assesses Interstitial Cystitis (Painful Bladder Syndrome) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Interstitial Cystitis (Painful Bladder Syndrome)”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Interstitial Cystitis (Painful Bladder Syndrome)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Interstitial Cystitis (Painful Bladder Syndrome) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“Alivio Therapeutics Inc

GlycoMira Therapeutics Inc

Grunenthal GmbH

Harrow Health Inc

Kyorin Pharmaceutical Co Ltd

Lipella Pharmaceuticals Inc

Mirae Cell Bio Co Ltd

Pierre Fabre Pharmaceuticals Inc

UCB SA

Urigen Pharmaceuticals Inc

Xigen SA”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Interstitial Cystitis (Painful Bladder Syndrome) Overview

Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Interstitial Cystitis (Painful Bladder Syndrome) Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Interstitial Cystitis (Painful Bladder Syndrome) Companies Involved in Therapeutics Development

Aquinox Pharmaceuticals Inc

Astellas Pharma Inc

Idera Pharmaceuticals Inc

Kyorin Pharmaceutical Co Ltd

Kytogenics Pharmaceuticals Inc

Lipella Pharmaceuticals Inc

UCB SA

Urigen Pharmaceuticals Inc

Xigen SA

Interstitial Cystitis (Painful Bladder Syndrome) Drug Profiles

(heparin sodium + lidocaine hydrochloride) Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Antisense Oligonucleotide to Inhibit NLRP3 for Inflammation, Interstitial Cystitis and Uveitis Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-6294 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brimapitide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

certolizumab pegol Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dimethyl sulfoxide Drug Profile

Product Description

Mechanism Of Action

R&D Progress

F-16357 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GM-0111 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ICE-3682 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lidocaine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LP-08 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mesalamine Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NEO-5937 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

onabotulinumtoxinA Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pentosan polysulfate sodium Drug Profile

Product Description

Mechanism Of Action

R&D Progress

rosiptor Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem Cell Therapy for Interstitial Cystitis and Metabolic Disorders Drug Profile

Product Description

Mechanism Of Action

R&D Progress

URG-801 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Interstitial Cystitis (Painful Bladder Syndrome) Dormant Projects

Interstitial Cystitis (Painful Bladder Syndrome) Discontinued Products

Interstitial Cystitis (Painful Bladder Syndrome) Product Development Milestones

Featured News & Press Releases

Feb 09, 2018: Aquinox Provides Enrollment Update for LEADERSHIP 301 Clinical Trial of Rosiptor

Dec 15, 2017: Aquinox Promotes Lloyd Mackenzie to Chief Operating Officer and Vice President, R&D Operations

Dec 07, 2017: Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome (IC/BPS)

Nov 08, 2017: Aquinox Pharmaceuticals Announces Third Quarter 2017 Financial Results

Aug 28, 2017: Aquinox Statement on FDA Advisory Committee Meeting to Discuss Interstitial Cystitis/Bladder Pain Syndrome

Oct 03, 2016: Aquinox Announces Appointment of Dr. Barbara Troupin as Chief Medical Officer

Sep 27, 2016: Idera Pharmaceuticals Presents New Third Generation Antisense (3GA) Data at the 12th Annual Meeting of the Oligonucleotide Therapeutics Society

Sep 06, 2016: Aquinox Pharmaceuticals Initiates Patient Dosing in LEADERSHIP 301 Phase 3 Clinical Trial of AQX-1125 in Interstitial Cystitis/Bladder Pain Syndrome

May 25, 2016: Aquinox Announces Executive Appointments

May 10, 2016: Aquinox Pharmaceuticals Announces First Quarter 2016 Financial Results

Jan 11, 2016: Aquinox Announces Update on Development Program for AQX-1125 Following Meeting With FDA

Dec 22, 2015: Aquinox Pharmaceuticals Announces Appointment of Ms. Shelley McCloskey as Vice President, Human Resources & Administration

Sep 18, 2015: Aquinox Presents at 2015 International Society for the Study of BPS Conference

Aug 27, 2015: Lipella Pharmaceuticals Announces Enrollment of First Patient in Phase-2 Trial in Interstitial Cystitis

Aug 25, 2015: LEADERSHIP Results Accepted for Podium Presentation at the 2015 Annual Meeting of the International Society for the Study of BPS

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products under Development by Universities/Institutes, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Universities/Institutes, H2 2019

Number of Products by Stage and Target, H2 2019

Number of Products by Stage and Mechanism of Action, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) – Pipeline by Alivio Therapeutics Inc, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) – Pipeline by GlycoMira Therapeutics Inc, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) – Pipeline by Grunenthal GmbH, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) – Pipeline by Harrow Health Inc, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) – Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) – Pipeline by Lipella Pharmaceuticals Inc, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) – Pipeline by Mirae Cell Bio Co Ltd, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) – Pipeline by Pierre Fabre Pharmaceuticals Inc, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) – Pipeline by UCB SA, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) – Pipeline by Urigen Pharmaceuticals Inc, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) – Pipeline by Xigen SA, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) – Dormant Projects, H2 2019

Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome) – Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development for Interstitial Cystitis (Painful Bladder Syndrome/Bladder Pain Syndrome), H2 2019

Number of Products under Development by Companies, H2 2019

Number of Products by Targets, H2 2019

Number of Products by Stage and Targets, H2 2019

Number of Products by Mechanism of Actions, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared